The National Veterinary Care Ltd (ASX: NVL) share price is down 0.8% after announcing that it has entered into binding agreements to acquire two clinics and it’s finalising terms for the acquisition of a third clinic.
Settlement of these acquisitions is expected to take place by 31 July 2018 and this will bring the total number of veterinary service businesses up to 67.
The new clinics are within existing National Veterinary Care’s geographical clusters in Queensland and Victoria. They are expected to generate revenue of $6 million and combined earnings before interest and tax (EBIT) of $1.84 million.
The total cost for the three acquisitions will be $9.6 million, which consists of $6.56 million upfront and a deferred component of $3.04 million.
The Managing Director, Tomas Steenackers, said “The acquisition of these high quality clinics will see National Vet Care start the new financial year having increased our portfolio by 14 clinics since 1 July 2017. These additional three clinics, collectively delivering higher than average annual revenue and strong EBIT margins, will bring total historical annual revenue for the 14 clinics to $20.7 million.”
Considering National Vet Care generated nearly $67 million of revenue in the 2017 financial year, this would suggest that National Vet Care will have added close to a third of additional annualised revenue since FY17.
This is another step on National Vet Care’s acquisition journey. The actual acquisitions appear to profitable and high quality, although the price seems to be a bit higher than what it has paid for other clinics in the past, when including the deferred amounts.
I’ll be interested to see how National Vet Care reports in a few months, but I can understand why the market reacted negatively to this news – there is a concern in the market around Greencross Limited’s (ASX: GXL) standalone vets.
If you’re not sold on the pet industry, then you should consider one of these top stocks instead.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor Tristan Harrison owns shares of NATVETCARE FPO. The Motley Fool Australia owns shares of NATVETCARE FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.